China
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
IP firm leaders share why they remain positive in the face of falling patent applications from US filers, and how they are meeting a rising demand from China
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
Despite a broader slowdown in US IP partner hiring in 2025, litigation demand drove aggressive lateral expansion at select firms
Sponsored
Sponsored
-
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Yifan Lu of Tahota Law Firm explore Beijing's pioneering role among eight Chinese provinces and municipalities designated to work on the development of the country’s data intellectual property rights framework -
Sponsored by Tahota Law FirmCharles Feng and Lian Xue of Tahota Law Firm analyse judicial interpretations of China’s Trademark Law and explain why the date of infringement should be the starting point for the ‘preceding three years’ non-use period
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm begins a two-part guide to intellectual property protection in China by considering the general provisions, before focusing on the key issues and legal framework concerning trademarks
-
Sponsored by Tahota Law FirmCharles Feng of Tahota Law Firm concludes a two-part series on intellectual property protection in China by looking at copyright, unfair competition, and a change to the appeals procedure for technology-related disputes
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies
